Europe is at the forefront of health tech innovation, with some of the best universities and most inspiring corporates in the world. Early-stage venture capital is needed to provide the funds to transform this untapped innovation into something better: solutions that benefit patients across the globe.
Simultaneously, investors are seeking outstanding returns for their investments, but they are struggling to gain access to quality opportunities. Moreover, transaction costs as they provide the needed capital to accelerate ventures. Yet they often struggle
NLC has set up several investment funds to provide investors access to a diversified portfolio of impactful healthtech ventures with one single investment, allowing them to spread their risk over multiple investments at low transaction costs.
If you are interested in joining our mission by combining healthy financial returns with creating real impact, please get in touch to learn more about our fund propositions.Get In Touch
Elithia Biotech Fund
Named after the Greek goddess of birth, NLC is now introducing the Elithia Biotech Fund: a unique way to translate breakthrough science into the next generation of impactful biotech ventures. By integrating NLC’s proven venture-building capabilities with a unique investment strategy and structure, the Elithia Biotech Fund will accelerate the development of these drugs from day one by investing in 22 promising, early-stage biotech projects within the fields of immunology and neurology.
If you would like to receive more information about this proposition, please get in touch.
Stepping Stone Fund
The Stepping Stone Fund was set up at the end of 2020 to invest in 40 promising new start-ups all built and supported by NLC. With a total fund size of €10.8M, the fund allows investors to be involved from the beginning by providing seed investments to companies when value creation and value potential are highest, with the possibility to follow the successful ventures through the fund’s three-tiered financing approach.
The first Stepping Stone Fund was such a success we will be launching the second Stepping Stone Fund in H2 2022. If you would like to receive more information about this, please get in touch.
Momentum was founded in early 2020 to provide seed capital to eleven life-changing ventures from the NLC portfolio. By the end of 2021, the fund was expanded (‘Momentum 1.1’) to provide follow-on financing to five of the ventures from the original portfolio as they have taken important de-risking steps in their development of bringing their solutions to the patient.
The Momentum fund is currently closed, and it is not possible to invest in this fund anymore at this stage.
This webpage has been prepared by NLC Fund Management B.V. (‘NLC’) with the purpose of sharing relevant information concerning the funds under their management. It does not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, which will only be made by means of an information memorandum and/or subscription documents. You may not rely on this webpage as the basis upon which to make an investment decision. This webpage does not purport to be complete on any topic addressed. NLC has not verified or analyzed the information included in this webpage for accuracy or completeness. NLC shall not bear any liability for the information contained in, or any omissions from, this webpage.SFDR Disclosure (Dutch)